Avista selling CRO BioReliance to Sigma-Aldrich

Private equity firm Avista Capital Partners will sell CRO BioReliance Corp. (Rockville, Md.) to Sigma-Aldrich Corp. (NASDAQ:SIAL) for $350 million in cash. Sigma-Aldrich said BioReliance recorded 2010...